Biomaterial Database

Interaction between 8-methoxypsoralen and phenytoin. Consequence for PUVA therapy. 1985

B Staberg, and B Hueg

A patient with epilepsy and psoriasis in phenytoin therapy was treated with PUVA with no effect at all. The PUVA treatment failure was demonstrated as being due to abnormally low serum levels of 8-methoxypsoralen (8-MOP) during phenytoin therapy, while normal serum levels of 8-MOP were observed after phenytoin was discontinued. The effect is probably due to an induction of the hepatic enzyme system by phenytoin, leading to an increased metabolism of 8-MOP. Other drugs with hepatic enzyme inducing properties might possibly also interfere with psoralen metabolism with further consequences for PUVA therapy.

UI	MeSH Term	Description	Entries
D008730	Methoxsalen	A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.	8-Methoxypsoralen,Ammoidin,Xanthotoxin,8-MOP,Deltasoralen,Dermox,Geroxalen,Meladinina,Meladinine,Meloxine,Methoxa-Dome,Méladinine,Oxsoralen,Oxsoralen-Ultra,Puvalen,Ultramop,8 MOP,8 Methoxypsoralen,8MOP,Methoxa Dome,Oxsoralen Ultra
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010672	Phenytoin	An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.	Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011565	Psoriasis	A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011701	PUVA Therapy	Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA).	Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D004347	Drug Interactions	The action of a drug that may affect the activity, metabolism, or toxicity of another drug.	Drug Interaction,Interaction, Drug,Interactions, Drug
D004827	Epilepsy	A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man